Displaying drugs 1701 - 1725 of 2565 in total
Ribavirin elaidate
Investigational
Matched Synonyms: … 1h-1,2,4-triazole-3-carboxamide, 1-(5-o-((9e)-1-oxo-9-octadecen-1-yl)-.beta.-d-ribofuranosyl)- …
Matched Iupac: … [(2R,3S,4R,5R)-5-(3-carbamoyl-1H-1,2,4-triazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (9E)-octadec-9-enoate …
Matched Iupac: … [(2R,3S,4R,5R)-5-(3-carbamoyl-1H-1,2,4-triazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (9E)-octadec-9-enoate …
2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID
Experimental
Matched Name: … 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID …
Matched Iupac: … 2-{[7-(carboxymethoxy)-9-(hydroxyimino)-9H-fluoren-2-yl]oxy}acetic acid …
Matched Iupac: … 2-{[7-(carboxymethoxy)-9-(hydroxyimino)-9H-fluoren-2-yl]oxy}acetic acid …
Topiroxostat
Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Xanthine oxidase inhibitors are classified into two groups; purine analogs such as...
Experimental
Efmarodocokin alfa
Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Investigational
7-Hydroxystaurosporine
Experimental
Investigational
Matched Iupac: … {7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-16-one ... 6R,18R)-18-hydroxy-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^ …
Lestaurtinib
Investigational
Matched Iupac: … {2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20(25),21,23-nonaen-3-one ... 15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^ …
Dideoxyadenosine
Investigational
Matched Synonyms: … 6-amino-9-(2',3'-dideoxy-.beta.-d-glycero-pentofuranosyl)purine ... 9-(2,3-dideoxy-.beta.-d-glycero-pentofuranosyl)-9h-purin-6-amine …
Matched Iupac: … [(2S,5R)-5-(6-amino-9H-purin-9-yl)oxolan-2-yl]methanol …
Matched Iupac: … [(2S,5R)-5-(6-amino-9H-purin-9-yl)oxolan-2-yl]methanol …
BTA9881
BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.
Investigational
99mTc-HYNIC (Tyr3)-octreotide
Investigational
Matched Iupac: … 99Tc)technetium(5+) 2-({2-[(carboxylatomethyl)amino]ethyl}amino)acetate 4-{[(4R,7S,10S,13R,16S,19R)-10 …
18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE
Experimental
Matched Iupac: … 7-chloro-11,17-dioxa-2,4,20,22-tetraazatricyclo[16.3.1.0^{5,10}]docosa-1(22),5(10),6,8,18,20-hexaen-3 …
11-Deoxy-Beta-Rhodomycin
Experimental
Matched Iupac: … (7R,8R,10S)-10-{[(2R,4S,5S,6S)-4-(dimethylamino)-5-{[(2S,4S,5R,6S)-4-hydroxy-6-methyl-5-{[(2R,6R)-6-methyl …
10-(4-Dimethylamino-5-Hydroxy-6-Methyl-Tetrahydro-Pyran-2-Yloxy)-8-Ethyl-1,8,11-Trihydroxy-7,8,9,10-Tetrahydro-Naphthacene-5,12-Dione
Experimental
Matched Name: … 10-(4-Dimethylamino-5-Hydroxy-6-Methyl-Tetrahydro-Pyran-2-Yloxy)-8-Ethyl-1,8,11-Trihydroxy-7,8,9,10-Tetrahydro-Naphthacene …
Matched Iupac: … (8S,10S)-10-{[(2R,4S,5S,6S)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]oxy}-8-ethyl-1,8,11-trihydroxy …
Matched Iupac: … (8S,10S)-10-{[(2R,4S,5S,6S)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]oxy}-8-ethyl-1,8,11-trihydroxy …
FP0011
FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.
Investigational
PF-06282999
Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).
Investigational
PF-03882845
PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.
Investigational
PF-04958242
PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing Loss, Sensorineural.
Investigational
PF-00610355
PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease, Asthma, Bronchial, and Bronchial Diseases, among others.
Investigational
PF-04447943
PF-04447943 has been investigated for the treatment of Alzheimer's Disease.
Investigational
PF-04691502
PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).
Investigational
PF-03635659
Pf03635659 has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.
Investigational
PF-06821497
PF-06821497 is under investigation in clinical trial NCT03460977 (PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma).
Investigational
PF-05089771
PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).
Investigational
PF-04937319
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Displaying drugs 1701 - 1725 of 2565 in total